Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754593 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL10067033 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL16452399 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL10067041 | 0.83 | MPI (0.32) | — | |
| SCHEMBL10067007 | 0.83 | MPI (0.32) | — | |
| SCHEMBL1392324 | 0.71 | — | — | |
| SCHEMBL2754592 | 0.71 | — | — | |
| SCHEMBL10067029 | 0.71 | — | — | |
| SCHEMBL14845625 | 0.69 | AKR1B1 (0.33) | — | |
| SCHEMBL7675790 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8101164-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | TSHR 1701/4885 |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | LGMN, TLL1, TEK | TSHR 2441/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | TSHR 3548/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | TSHR 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.